SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2022 Biotech Charity Contest
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Aloner11/17/2022 7:46:28 PM
   of 267
 
PRVB wins approval for Teplizumab, up over 11% AH:

The US FDA has granted approval to Provention Bio (NASDAQ: PRVB) for Tzield (teplizumab) to delay the onset of stage 3 of type 1 diabetes (T1D).The first-in-class medicine is given via intravenous infusion daily for 14 consecutive days.The therapy works by binding to specific immune system cells. It may also deactivate the immune cells that attack insulin-producing cells, while increasing the amount of cells that can moderate an immune response.Approval was based on the results of a placebo-controlled trial that showed over a median follow-up of 51 months, 45% of patients who received Tzield were later diagnosed with stage 3 T1D, compared to 72% of those on a placebo.Provention Bio ( PRVB) shares soared earlier in November after the FDA issued proposed labeling for teplizumab.
  • Report TOU ViolationShare This Post
     Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

    HomeMailHotSubjectMarksPeopleMarksKeepersSettings
    Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
    © 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News